SOURCE: Antisense Therapeutics

 

MELBOURNE, AUSTRALIA--(Marketwire - October 27, 2008) - Antisense Therapeutics Limited (ASX: ANP) today announced that the Company is scheduled to present at the Rodman & Renshaw 10th Annual Global Healthcare Conference, on November 10-12, at the New York Palace Hotel in New York City.

Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a presentation on November 12, at 12:25 p.m. EST on the Company's drug development pipeline, and the recent completion of a successful Phase IIa clinical trial with its lead compound, ATL1102, which has been licensed to Teva Pharmaceutical Industries (Teva). The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.antisense.com.au.

A replay of the presentation will be archived for 90 days after the conference, at the same location. For more information about the Rodman & Renshaw 10th Annual Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

Antisense management will be available for meetings in New York on November 11-14.

In September, the results from the ATL/TV1102 Phase IIa clinical trial in patients with MS were presented at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada by the Principal Investigator for the trial, Volker Limmroth, M.D., Ph.D., Chairman of the Department of Neurology, Cologne City Hospitals, Germany.

In the study, it was demonstrated that ATL/TV1102, a second-generation antisense drug designed to specifically inhibit the production of VLA-4 (a clinically validated target in MS), significantly reduced the number of new active lesions in patients with Relapsing Remitting MS taking ATL/TV1102 for 8 weeks. The development of ATL/TV1102 as an MS treatment continues with ANP's licensing partner Teva.

Earlier this month, the Company reported positive results from its collaborative preclinical research study on the therapeutic potential of ATL1101 in prostate cancer. ATL1101 is a second-generation antisense inhibitor of the insulin-like growth factor-I receptor (IGF-IR), which has previously shown potent activity in laboratory studies, including in human cancer cells.

The key findings from the research study were that ATL1101 injections significantly suppressed the growth of the human prostate tumors and slowed down their transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer. These results were presented at New York Academy of Sciences Annual Meeting of the Oligonucleotide Therapeutics Society, Harvard Conference Center in Boston.

About Antisense Therapeutics Limited: Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.

Website: www.antisense.com.au